- Page 2 and 3: PHARMACEUTICAL TECHNOLOGY Controlle
- Page 4 and 5: 3 TABLET MACHINE INSTRUMENTATION IN
- Page 6 and 7: First published in 1991 by ELLIS HO
- Page 8 and 9: 7 10 Controlled delivery of theophy
- Page 12: Matrix formulations
- Page 15 and 16: 14 MATRIX FORMULATIONS [CH. 1 lacto
- Page 17 and 18: 16 MATRIX FORMULATIONS [CH. 1 Table
- Page 19 and 20: 18 MATRIX FORMULATIONS [CH. 1 Fig.
- Page 21 and 22: 20 MATRIX FORMULATIONS [CH. 1 Fig.
- Page 24 and 25: 2 The effect of electrolytes and dr
- Page 26 and 27: CH. 2] THE EFFECT OF ELECTROLYTES A
- Page 28 and 29: CH. 2] THE EFFECT OF ELECTROLYTES A
- Page 30 and 31: CH. 2] THE EFFECT OF ELECTROLYTES A
- Page 32 and 33: CH. 2] THE EFFECT OF ELECTROLYTES A
- Page 34 and 35: 3 Factors affecting the formulation
- Page 36 and 37: MATRIX FORMULATIONS [CH. 3 35 Fig.
- Page 38 and 39: MATRIX FORMULATIONS [CH. 3 37 Table
- Page 40 and 41: Table 3—Comparison of fits using
- Page 42: MATRIX FORMULATIONS [CH. 3 41 Fig.
- Page 45 and 46: 44 CH. 4] STATISTICAL OPTIMIZATION
- Page 47 and 48: 46 CH. 4] STATISTICAL OPTIMIZATION
- Page 49 and 50: 48 CH. 4] STATISTICAL OPTIMIZATION
- Page 51 and 52: 50 CH. 4] STATISTICAL OPTIMIZATION
- Page 53 and 54: 52 CH. 4] STATISTICAL OPTIMIZATION
- Page 55 and 56: 54 CH. 4] STATISTICAL OPTIMIZATION
- Page 58 and 59: 5 Analysis of different parameters
- Page 60 and 61:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 62 and 63:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 64 and 65:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 66 and 67:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 68 and 69:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 70:
CH. 5] AN OPTIMIZED PROLONGED RELEA
- Page 73 and 74:
72 MATRIX FORMULATIONS [CH. 6 The a
- Page 75 and 76:
74 MATRIX FORMULATIONS [CH. 6 Fig.
- Page 77 and 78:
76 MATRIX FORMULATIONS [CH. 6 Fig.
- Page 79 and 80:
78 MATRIX FORMULATIONS [CH. 6 Parti
- Page 81 and 82:
80 MATRIX FORMULATIONS [CH. 7 Preli
- Page 83 and 84:
82 MATRIX FORMULATIONS [CH. 7 Prepa
- Page 85 and 86:
84 MATRIX FORMULATIONS [CH. 7 Fig.
- Page 87 and 88:
86 MATRIX FORMULATIONS [CH. 7 Fig.
- Page 90 and 91:
8 Topical release and permeation st
- Page 92 and 93:
MATRIX FORMULATIONS [CH. 8 91 EXPER
- Page 94 and 95:
MATRIX FORMULATIONS [CH. 8 93 Table
- Page 96 and 97:
MATRIX FORMULATIONS [CH. 8 95 Table
- Page 98 and 99:
MATRIX FORMULATIONS [CH. 8 97 Table
- Page 100 and 101:
MATRIX FORMULATIONS [CH. 8 99 Table
- Page 102 and 103:
Multiparticulates
- Page 104 and 105:
9 Polyacrylate (Eudragit retard) mi
- Page 106 and 107:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 108 and 109:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 110 and 111:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 112 and 113:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 114 and 115:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 116 and 117:
CH. 9] POLYACRYLATE (EUDRAGIT RETAR
- Page 118 and 119:
10 Controlled delivery of theophyll
- Page 120 and 121:
MULTIPARTICULATES [CH. 10 119 Micro
- Page 122 and 123:
MULTIPARTICULATES [CH. 10 121 Fig.
- Page 124 and 125:
MULTIPARTICULATES [CH. 10 123 Fig.
- Page 126 and 127:
11 The effect of food on gastrointe
- Page 128 and 129:
MULTIPARTICULATES [CH. 11 127 Fig.
- Page 130 and 131:
MULTIPARTICULATES [CH. 11 129 Fig.
- Page 132 and 133:
12 Biodegradable polymers: Effect o
- Page 134 and 135:
MULTIPARTICULATES [CH. 12 133 Table
- Page 136 and 137:
MULTIPARTICULATES [CH. 12 135 Fig.
- Page 138 and 139:
MULTIPARTICULATES [CH. 12 137 Fig.
- Page 140 and 141:
MULTIPARTICULATES [CH. 12 139 Fig.
- Page 142 and 143:
13 A comparison of dissolution prop
- Page 144 and 145:
MULTIPARTICULATES [CH. 13 143 rev m
- Page 146 and 147:
MULTIPARTICULATES [CH. 13 145 accom
- Page 148 and 149:
MULTIPARTICULATES [CH. 13 147 Fig.
- Page 150 and 151:
MULTIPARTICULATES [CH. 13 149 Fig.
- Page 152 and 153:
MULTIPARTICULATES [CH. 13 151 15 []
- Page 154 and 155:
Ophthalmic formulation
- Page 156 and 157:
14 In vitro-in vivo comparison of t
- Page 158 and 159:
CH. 14] COMPARISON OF TIMOLOL MALEA
- Page 160 and 161:
CH. 14] COMPARISON OF TIMOLOL MALEA
- Page 162 and 163:
15 Preparation and evaluation of a
- Page 164 and 165:
OPHTHALMIC FORMULATION [CH. 15 163
- Page 166 and 167:
OPHTHALMIC FORMULATION [CH. 15 165
- Page 168 and 169:
OPHTHALMIC FORMULATION [CH. 15 167
- Page 170 and 171:
Implants
- Page 172 and 173:
16 Release kinetics of tobramycin s
- Page 174 and 175:
CH. 16] TOBRAMYCIN SULPHATE FROM PO
- Page 176 and 177:
CH. 16] TOBRAMYCIN SULPHATE FROM PO
- Page 178 and 179:
CH. 16] TOBRAMYCIN SULPHATE FROM PO
- Page 180 and 181:
CH. 16] TOBRAMYCIN SULPHATE FROM PO
- Page 182 and 183:
CH. 16] TOBRAMYCIN SULPHATE FROM PO
- Page 184 and 185:
17 Formulation of silicone matrix s
- Page 186 and 187:
IMPLANTS [CH. 17 185 Table 1—Revi
- Page 188 and 189:
IMPLANTS [CH. 17 187 Table 2—Resu
- Page 190 and 191:
IMPLANTS [CH. 17 189 Fig. 4—Weigh
- Page 192 and 193:
IMPLANTS [CH. 17 191 release profil
- Page 194 and 195:
Index additives, 26 aminophylline,
- Page 196:
INDEX 195 nifedipine, 103 non-linea